LY 293111 clinical trials
Also written LY293111.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2000
How each study uses LY 293111 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY293111
- 3
Studies by the year they started
3 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2003 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Eli Lilly and Company (2) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses LY 293111 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- LY293111 in Treating Patients With Advanced Solid TumorsCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00006375Written as LY293111
- A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung CancerCompletedPhase 2Eli Lilly and CompanyNCT00069875Written as LY293111
- A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic CancerCompletedPhase 2Eli Lilly and CompanyNCT00055250Written as LY293111